Tin tức & Cập nhật
Lọc theo Chuyên ngành:
Sustained benefits with ocrelizumab in relapsing-remitting MS
Patients with relapsing-remitting multiple sclerosis (RRMS) who have suboptimal response to disease-modifying therapies (DMTs) experienced low disease activity after switching to ocrelizumab, according to interim results of the LIBERTO study.
Sustained benefits with ocrelizumab in relapsing-remitting MS
19 May 2022
Tofacitinib on par with TNFi in rheumatoid arthritis
Tofacitinib demonstrates similar physician- and patient-reported effectiveness to tumour necrosis factor inhibitors (TNFi) in rheumatoid arthritis (RA), according to a study.
Tofacitinib on par with TNFi in rheumatoid arthritis
19 May 2022
Short-course IV antibiotics should be considered for nonbacteraemic UTI in babies
In the treatment of young infants with nonbacteraemic urinary tract infection (UTI), administering intravenous (IV) antibiotics for less than 48 hours appears to work well in the absence of meningitis, with low rates of treatment failure and serious complications, according to a study.
Short-course IV antibiotics should be considered for nonbacteraemic UTI in babies
18 May 2022
Relugolix combo improves uterine fibroid symptoms regardless of fibroid location
Combination therapy with relugolix (once daily relugolix 40 mg, estradiol 1 mg, norethindrone acetate 0.5 mg) leads to improvement in heavy menstrual bleeding (HMB) and in other uterine fibroid (UF)-related symptoms independent of the location of the largest fibroid, results of a recent study have shown.
Relugolix combo improves uterine fibroid symptoms regardless of fibroid location
17 May 2022
Beta-blockers reduce mortality risk in older patients with HFrEF
Use of beta-blockers results in a lower risk of all-cause mortality, but not of heart failure (HF) readmission, in older patients with HR with reduced ejection fraction (HFrEF), reports a recent study. Results are similar between patients admitted and not admitted from nursing homes.